CClinicalTrials.gg
RecruitingNCT06287983Updated Mar 7, 2024

Effect of Inspiratory Muscle Training on Respiratory Functions and Exercise Capacity

An interventional study of Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic) and The Sample Spondylitis Exercise Program in Ankylosing Spondylitis, sponsored by Kayseri City Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Kayseri City Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jun 2023, registered Feb 2024).
  • Started Jun 2023; still recruiting 3 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In this study, we aimed to evaluate the effect of Anti- tumor necrosis factor (TNF) treatment on pulmonary functions in patients with AS and to evaluate the pulmonary functions and exercise performance of patients by adding inspiratory muscle training to spinal mobility exercises in patients with AS using Anti-TNF. We also aimed to investigate the relationship between these parameters and disease activity, spinal mobility and quality of life.

Read the detailed description

Patients diagnosed with AS who applied to outpatient clinic, received anti- tumor necrosis factor (TNF) treatment for at least 6 months and have been evaluated will be included in the study.

Patients who agree to participate in the study will be asked to sign a consent form. At the beginning, all patients' name-surname, age, height, body weight, body mass index, smoking-alcohol use, profession, marital status, education, duration of ankylosing spondylitis disease, history of corticosteroid use, presence of systemic and extra-articular involvement, medications used and additional diseases will be questioned and recorded in their files.

It was planned to include 30 male and 14 female patients in the study by calculating the female/male ratio of patients diagnosed with As who applied to hospital in the last year and in line with the literature. A total of 44 patients will be randomly randomized into 2 groups using the sealed envelope randomization method. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.

The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3*10 sets.

Inspiratory muscle training will also be added to the intervention group.

Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.

Patients included in the study were evaluated with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), BASFI(Bath Ankylosing Spondylitis Functional Index), ASQoL(The Ankylosing Spondylitis Quality of Life), Modified Borg Scale, measurement of dyspnea at maximum exercise with Visual Analog Scale (VAS), 6-minute walk test, chest expansion measurement and respiratory function test (spirometry) at 0, 6, 12 and 24 weeks will be evaluated.

02

Conditions studied

03

In context

Spondylitis

623 studies on the registry are indexed under Spondylitis; 83 are open to participants now.

This study's planned enrollment of 44 is below the median of 92 across 349 interventional studies indexed under Spondylitis.

Browse Spondylitis studies →

Lead sponsor

Kayseri City Hospital is the lead sponsor of 47 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with ankylosing spondylitis according to the Modified New York Criteria
  • Patients with BASDAI score \<4.1 who received Anti-TNF therapy for at least 6 months
  • Patients whose maximum inspiratory pressure value is \<80% in the Pulmonary Function Test
  • Patients who had a cardiac examination within the last year and no cardiac pathology was detected.

Exclusion criteria

Exclusion Criteria:

  • The patient has a serious mental disorder
  • Presence of neurological and pulmonary disease that would prevent the patient from using the PFT device
  • Presence of uncontrolled hypertension
  • Presence of uncontrolled diabetes
  • Presence of uncontrolled cardiac arrhythmia
  • Uncontrolled heart failure
  • High-risk unstable angina and all acute cardiac diseases (acute myocardial infarction, acute endocarditis, myocarditis or pericarditis)
  • Symptomatic severe aortic stenosis
  • Acute pulmonary embolism or pulmonary infarction
  • Severe pulmonary hypertension
  • Presence of systemic infection or malignancy
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    EXERCISE GROUP

    The Sample Spondylitis Exercise Program

    Other: The Sample Spondylitis Exercise Program

  • Active comparator
    EXERCISE+ Inspiratory muscle trainer (IMT) GROUP

    The Sample Spondylitis Exercise Program Inspiratory muscle training will also be added to the intervention group.

    Device: Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic) · Other: The Sample Spondylitis Exercise Program

Interventions

  • DeviceInspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)

    Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.

  • OtherThe Sample Spondylitis Exercise Program

    The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Respiratory function test (Spirometry)

    Spirometry is the most commonly used respiratory function test (PFT). It is a physiological test based on measuring the flow or volume changes that occur during breathing as a derivative of time. The standard maneuver used during spirometry is also called the forced expiratory maneuver; It consists of rapid and deep inspiration followed by maximal expiration at the level of total lung volume. The spirometry test to be evaluated must comply with the previously defined spirometry test performance standards, acceptability and repeatability criteria. In the study, the most frequently measured spirometric parameters with forced expiration maneuver were; vital capacity (VC), forced vital capacity (FVC), forced expiratory volume (FEV), maximum inspiratory pressure (PImax) and maximum expiratory pressure (Pemax) to evaluate respiratory muscle strength will be checked.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

Secondary outcomes

  1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI):

    It evaluates disease-specific symptoms such as fatigue, spinal and peripheral joint pain, swelling and morning stiffness and is interpreted on a score ranging from 0-10. An increase in the score indicates an increase in disease activity. It is a reliable and sensitive index developed to evaluate disease activity and progression.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  2. Bath Ankylosing Spondylitis Functional Index (BASFI)

    It is a fast and easy-to-apply, sensitive and reliable index developed to determine and monitor the functional status of patients with AS. It consists of 10 questions that evaluate patients' abilities to bend, reach, stand, change positions, climb stairs, and cope with activities of daily living. For each question, the final score is obtained by dividing the total score by 10 using VAS in the range of 0-10 cm.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  3. Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)

    ASQoL is the most widely used, valid and reliable questionnaire to evaluate the quality of life in AS. In this survey, which consists of eighteen questions, patients are asked to answer yes or no to each question. '0' points are taken for a no answer and '1' point is taken for a yes answer. Total score varies between 0-18. High scores indicate serious impairments in quality of life.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  4. Modified Borg Scale

    It is a scale frequently used to evaluate the severity of exertion dyspnea and resting dyspnea severity. It consists of ten items that describe the severity of dyspnea according to its degree. Defining the severity of dyspnea in the Modified Borg Scale makes it easier for patients to apply.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  5. Measurement of dyspnea at maximum exercise with the Visual Analog Scale (VAS)

    Visual Analog Scale (VAS) is a scale applied by marking with a pencil on a horizontal or vertical line of one hundred millimeters. There is no dyspnea at the 0 mm point of this line, and the most severe dyspnea is at the 100 mm point. The patient marks the severity of the current respiratory distress on the scale using these two degrees as criteria. Scoring is done by measuring the marked point with the help of a tape measure. Most of the studies conducted to date indicate that VAS is a reliable scale that can be used to evaluate the severity of dyspnea, and that it is even sensitive to minute changes in the severity of dyspnea.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  6. 6-minute walk test (6MWT)

    It is a frequently used test in cardiopulmonary rehabilitation to monitor exercise capacity and treatment effectiveness. The patient should rest by sitting in a chair for 15 minutes before the test and wear appropriate shoes and comfortable clothing. Calculate the distance walked by the patient at their own walking pace in 6 minutes, preferably in a 30-meter long corridor. If the patient's O2 saturation (sO2) is \<88%, the test should be performed with O2 support.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

  7. Chest expansion measurement

    Chest expansion is measured at the fourth intercostal space. The patient is asked to exhale all the air in his lungs and then take deep inspiration. As a result of deep inspiration, the expansion around the chest is recorded in centimeters.

    Time frame: before treatment (day 0), after treatment (week 6), after treatment (week 12), after treatment (week 24)

07

Study locations

1 of 1 sites recruiting
  • Health Sciences University, Kayseri Medicine Faculty, Kayseri City Hospital
    Kayseri, 38080, Turkey
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06287983
Lead sponsor
Kayseri City Hospital
Responsible party
Havva Talay Çalış (professor doctor, Kayseri City Hospital) — Principal investigator
First posted
Mar 1, 2024
Start date
Jun 1, 2023
Primary completion
Mar 31, 2024 (estimated)
Completion
May 15, 2024 (estimated)
Last update
Mar 7, 2024

Study contacts

Havva Talay Calıs, Prof
Contact
htalaycalis@yahoo.com
+90532 687 45 41
Esra Yaprak tas, MD
Contact
yaprak8100@gmail.com
+905062007571
Serap Tomruk Sütbeyaz, Prof
study director · Saglik Bilimleri Universitesi
Esra Yaprak tas
principal investigator · Saglik Bilimleri Universitesi

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion